|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 72.47 USD | +1.74% |
|
-3.85% | +9.19% |
| 06-16 | AI Can Play 'Significant' Role in Tech for Managing Diabetes, Says David Roman | MT |
| 06-15 | Piper Sandler Adjusts Price Target on DexCom to $88 From $75, Maintains Overweight Rating | MT |
Company Valuation: DexCom, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 52,042 | 43,740 | 47,945 | 30,377 | 25,885 | 27,964 | - | - |
| Change | - | -15.95% | 9.61% | -36.64% | -14.79% | 8.03% | - | - |
| Enterprise Value (EV) 1 | 52,692 | 45,068 | 49,813 | 31,073 | 26,209 | 27,595 | 26,717 | 25,610 |
| Change | - | -14.47% | 10.53% | -37.62% | -15.65% | 5.29% | -3.18% | -4.14% |
| P/E | 346x | 138x | 95.5x | 54.8x | 31.8x | 29.6x | 24.8x | 20.6x |
| PBR | 23.1x | 20.5x | 23.1x | 15.1x | 9.3x | 10.7x | 10.4x | 7.55x |
| PEG | - | 1x | 1.6x | 5.94x | 0.7x | 1.7x | 1.3x | 1x |
| Capitalization / Revenue | 21.3x | 15x | 13.2x | 7.53x | 5.55x | 5.35x | 4.8x | 4.29x |
| EV / Revenue | 21.5x | 15.5x | 13.8x | 7.7x | 5.62x | 5.28x | 4.58x | 3.92x |
| EV / EBITDA | 111x | 60x | 49.1x | 28.1x | 19.4x | 16.8x | 14x | 11.5x |
| EV / EBIT | 142x | 92.9x | 69.3x | 41x | 27x | 22.8x | 18.6x | 14.9x |
| EV / FCF | 989x | 148x | 97.3x | 49.3x | 24.3x | 27.8x | 21.5x | 16.9x |
| FCF Yield | 0.1% | 0.68% | 1.03% | 2.03% | 4.11% | 3.6% | 4.65% | 5.92% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.3875 | 0.82 | 1.3 | 1.42 | 2.09 | 2.448 | 2.921 | 3.51 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 2,448 | 2,910 | 3,622 | 4,033 | 4,662 | 5,225 | 5,830 | 6,525 |
| EBITDA 1 | 472.7 | 751.6 | 1,014 | 1,105 | 1,349 | 1,639 | 1,914 | 2,227 |
| EBIT 1 | 370.7 | 485.1 | 718.6 | 757.1 | 969.3 | 1,212 | 1,438 | 1,723 |
| Net income 1 | 154.7 | 341.2 | 541.5 | 576.2 | 836.3 | 962.6 | 1,158 | 1,378 |
| Net Debt 1 | 650.1 | 1,328 | 1,868 | 695.9 | 323.2 | -369.5 | -1,248 | -2,354 |
| Reference price 2 | 134.24 | 113.24 | 124.09 | 77.77 | 66.37 | 72.47 | 72.47 | 72.47 |
| Nbr of stocks (in thousands) | 387,688 | 386,258 | 386,374 | 390,595 | 390,016 | 385,873 | - | - |
| Announcement Date | 2/10/22 | 2/9/23 | 2/8/24 | 2/13/25 | 2/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 29.61x | 5.28x | 16.83x | -.--% | 27.96B | |
| 22.24x | 3.3x | 12.38x | 2.88% | 154B | |
| 19.94x | 3.45x | 12.41x | 3.6% | 102B | |
| 34.44x | 8.39x | 21.94x | 1.17% | 56.51B | |
| 14.32x | 0.17x | 10.77x | 0.87% | 52.89B | |
| 35.88x | 2.9x | 9.94x | 2.67% | 39.67B | |
| 34.4x | 1.28x | 11.29x | 0.23% | 30.39B | |
| 38.95x | 6.73x | 24.3x | 0.27% | 23.17B | |
| 23.99x | 3.06x | 12.49x | 1.35% | 20.35B | |
| 22.29x | 3.27x | 11.75x | 1.3% | 19.75B | |
| Average | 27.61x | 3.78x | 14.41x | 1.43% | 52.65B | |
| Weighted average by Cap. | 25.23x | 3.66x | 13.74x | 2.08% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- DXCM Stock
- Valuation DexCom, Inc.
Select your edition
All financial news and data tailored to specific country editions
